CartalaxvsGlutathione

Molecular Formula

C₁₂H₁₉N₃O₈

Molecular Weight

333.3 g/mol

Half-Life

Short plasma half-life typical of tripeptides (minutes to hours); biological effects persist for weeks to months through epigenetic gene regulation; metabolized to constituent amino acids

Bioavailability

Orally bioavailable via intestinal peptide transporters (PepT1/PepT2, LAT1); 10-fold more potent than crude cartilage polypeptide complex at chondrogenic activation (200 vs 2000 ng/mL effective concentration)

CAS Number

Not yet registered (research compound)

Molecular Formula

C₁₀H₁₇N₃O₆S

Molecular Weight

307.33 g/mol

Half-Life

Very short in blood — roughly 2 to 10 minutes as intact glutathione; tissue pools turn over more slowly

Bioavailability

Low by mouth — intact glutathione is largely broken down in the gut by gamma-glutamyl transpeptidase; liposomal, intranasal, IV and inhaled routes bypass this

CAS Number

70-18-8

Common

• Mild injection site reaction
• Mild GI discomfort
• Mild fatigue
• Transient joint stiffness

Uncommon

• Temporary increase in joint discomfort

Serious

• No documented serious adverse effects

Common

• Generally well tolerated
• Unpleasant smell or taste

Uncommon

• Mild stomach upset, bloating or loose stools
• Transient cough

Serious

• Bronchospasm (airway tightening) in asthma

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Cartalax (polypeptide complex from bovine cartilage) has not undergone formal FDA approval or rigorous clinical safety trials. The safety profile is based on traditional use in Russia and Eastern Europe as a cartilage extract supplement, with limited published safety data. As a complex mixture of polypeptides, collagens, and proteoglycans, the actual active components and their pharmacology are undefined, making toxicity prediction impossible. Potential allergic reactions to bovine proteins exist, and contamination risks from source animal tissues cannot be ruled out without pharmaceutical manufacturing standards.

Contraindications

• xKnown hypersensitivity to peptide bioregulators or constituent amino acids (alanine, glutamic acid, aspartic acid)
• xPregnancy and breastfeeding — insufficient reproductive safety data
• xActive joint infection — treat infection before initiating peptide bioregulator therapy
• xMalignant bone or cartilage tumors — proliferative effects of peptide bioregulators may be contraindicated

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Sold as a dietary supplement; not FDA-approved as a drug. IV and inhaled uses are off-label/compounded.

Safety Overview

Glutathione has a reassuring safety record in trials, but the trials are small. In the 6-month oral trial (54 healthy adults taking 250 or 1,000 mg a day), blood glutathione rose and returned to baseline after a 1-month washout [2]. In the IV Parkinson's trial (21 people: 11 on 1,400 mg three times a week, 10 on placebo), reported adverse events were similar in the two groups and no one withdrew because of them [1]. Intranasal glutathione was tolerated over 3 months in a 30-person trial (placebo, 300 or 600 mg per day) with no substantial difference in adverse events between groups [9]; in the follow-up 45-person trial, one of the 15 people on the highest dose (200 mg three times daily) developed cardiomyopathy — a weakening of the heart muscle [10]. The clearest warning is for the inhaled form: in 8 people with mild asthma, nebulized glutathione (600 mg) dropped lung function (FEV1) 19% versus 1% after placebo, with coughing in 4 of 8 and breathlessness in 3 of 8 — the researchers attributed the airway narrowing to sulfite formation [5].

Contraindications

• xKnown allergy to glutathione or a product ingredient
• xAsthma — inhaled/nebulized forms can trigger airway tightening, especially in sulfite-sensitive people